[HTML][HTML] JM2, encoding a fork head–related protein, is mutated in X-linked autoimmunity–allergic disregulation syndrome

TA Chatila, F Blaeser, N Ho… - The Journal of …, 2000 - Am Soc Clin Investig
TA Chatila, F Blaeser, N Ho, HM Lederman, C Voulgaropoulos, C Helms, AM Bowcock
The Journal of clinical investigation, 2000Am Soc Clin Investig
X-linked autoimmunity–allergic disregulation syndrome (XLAAD) is an X-linked recessive
immunological disorder characterized by multisystem autoimmunity, particularly early-onset
type 1 diabetes mellitus, associated with manifestations of severe atopy including eczema,
food allergy, and eosinophilic inflammation. Consistent with the allergic phenotype, analysis
of two kindreds with XLAAD revealed marked skewing of patient T lymphocytes toward the
Th2 phenotype. Using a positional-candidate approach, we have identified in both kindreds …
X-linked autoimmunity–allergic disregulation syndrome (XLAAD) is an X-linked recessive immunological disorder characterized by multisystem autoimmunity, particularly early-onset type 1 diabetes mellitus, associated with manifestations of severe atopy including eczema, food allergy, and eosinophilic inflammation. Consistent with the allergic phenotype, analysis of two kindreds with XLAAD revealed marked skewing of patient T lymphocytes toward the Th2 phenotype. Using a positional-candidate approach, we have identified in both kindreds mutations in JM2, a gene on Xp11. 23 that encodes a fork head domain–containing protein. One point mutation at a splice junction site results in transcripts that encode a truncated protein lacking the fork head homology domain. The other mutation involves an in-frame, 3-bp deletion that is predicted to impair the function of a leucine zipper dimerization domain. Our results point to a critical role for JM2 in self tolerance and Th cell differentiation.
This article may have been published online in advance of the print edition. The date of publication is available from the JCI website, http://www. jci. org. J. Clin. Invest. 106: R75–R81 (2000).
The Journal of Clinical Investigation